Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$87.58−2.62 (-2.90%)
Close on Nov 13, 2026Market cap $6.88BP/E –Yield –
Abivax operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Abivax's operating cash flow for the twelve months ending Jun 30, 2026 was -€197.02M. For fiscal 2025 it was -€161.13M. The highest annual figure on record is -€45.05M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€161.13M | – |
| FY2024 | Dec 31, 2024 | -€154.07M | – |
| FY2023 | Dec 31, 2023 | -€97.13M | – |
| FY2022 | Dec 31, 2022 | -€53.94M | – |
| FY2021 | Dec 31, 2021 | -€45.05M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€51.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -€50.52M | – |
| Q4 FY2025 | Dec 31, 2025 | -€23.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -€71.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -€33.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -€33.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -€33.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -€35.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -€50.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -€34.75M | – |
See a number that looks wrong?